190 related articles for article (PubMed ID: 29032266)
61. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
[TBL] [Abstract][Full Text] [Related]
62. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.
Hong S; Brazauskas R; Hebert KM; Ganguly S; Abdel-Azim H; Diaz MA; Beattie S; Ciurea SO; Szwajcer D; Badawy SM; Gratwohl AA; LeMaistre C; Aljurf MDSM; Olsson RF; Bhatt NS; Farhadfar N; Yared JA; Yoshimi A; Seo S; Gergis U; Beitinjaneh AM; Sharma A; Lazarus H; Law J; Ulrickson M; Hashem H; Schoemans H; Cerny J; Rizzieri D; Savani BN; Kamble RT; Shaw BE; Khera N; Wood WA; Hashmi S; Hahn T; Lee SJ; Rizzo JD; Majhail NS; Saber W
Cancer; 2021 Feb; 127(4):609-618. PubMed ID: 33085090
[TBL] [Abstract][Full Text] [Related]
63. Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups.
Garcia-Horton A; Cyriac SL; Gedde-Dahl T; Floisand Y; Remberger M; Mattsson J; Michelis FV
Eur J Haematol; 2022 Dec; 109(6):672-679. PubMed ID: 36028979
[TBL] [Abstract][Full Text] [Related]
64. The Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation.
Shibasaki Y; Suwabe T; Katagiri T; Tanaka T; Kobayashi H; Fuse K; Ushiki T; Sato N; Yano T; Kuroha T; Hashimoto S; Narita M; Furukawa T; Sone H; Masuko M
Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28871665
[TBL] [Abstract][Full Text] [Related]
65. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
[TBL] [Abstract][Full Text] [Related]
66. Prediction of clinical outcome by controlling nutritional status (CONUT) before allogeneic hematopoietic stem cell transplantation in myeloid malignancies.
Araie H; Kawaguchi Y; Okabe M; Lee Y; Ohbiki M; Osaki M; Goto M; Goto T; Morishita T; Ozawa Y; Miyamura K
Int J Hematol; 2019 Nov; 110(5):599-605. PubMed ID: 31407255
[TBL] [Abstract][Full Text] [Related]
67. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
[TBL] [Abstract][Full Text] [Related]
68. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
69. Interactive Web Application for Plotting Personalized Prognosis Prediction Curves in Allogeneic Hematopoietic Cell Transplantation Using Machine Learning.
Okamura H; Nakamae M; Koh S; Nanno S; Nakashima Y; Koh H; Nakane T; Hirose A; Hino M; Nakamae H
Transplantation; 2021 May; 105(5):1090-1096. PubMed ID: 32541556
[TBL] [Abstract][Full Text] [Related]
70. Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation.
Armenian SH; Xiao M; Berano Teh J; Lee B; Chang HA; Mascarenhas K; Lee S; Iukuridze A; Xie JJ; Scott JM; Jones LW; Lennie Wong F; Forman SJ; Nakamura R
J Natl Cancer Inst; 2019 Aug; 111(8):837-844. PubMed ID: 30951603
[TBL] [Abstract][Full Text] [Related]
71. Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience.
Malard F; Chevallier P; Guillaume T; Delaunay J; Rialland F; Harousseau JL; Moreau P; Mechinaud F; Milpied N; Mohty M
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1217-23. PubMed ID: 24769328
[TBL] [Abstract][Full Text] [Related]
72. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
73. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
74. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
75. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
[TBL] [Abstract][Full Text] [Related]
76. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
77. Clinical Impact of Pretransplantation Physical Function on Transplantation after Allogeneic Hematopoietic Cell Transplantation in Older Adults.
Gomyo A; Kimura SI; Suzuki J; Ishikawa T; Meno T; Matsuoka A; Nakamura Y; Kawamura M; Kawamura S; Takeshita J; Yoshino N; Misaki Y; Yoshimura K; Okada Y; Akahoshi Y; Tamaki M; Kusuda M; Kameda K; Wada H; Sato M; Tanihara A; Sekine K; Nakasone H; Kako S; Kanda Y
Transplant Cell Ther; 2023 Nov; 29(11):721.e1-721.e8. PubMed ID: 37643718
[TBL] [Abstract][Full Text] [Related]
78. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
79. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.
Guièze R; Damaj G; Pereira B; Robin M; Chevallier P; Michallet M; Vigouroux S; Beguin Y; Blaise D; El Cheikh J; Roos-Weil D; Thiebaut A; Rohrlich PS; Huynh A; Cornillon J; Contentin N; Suarez F; Lioure B; Mohty M; Maillard N; Clement L; François S; Guillerm G; Yakoub-Agha I
Biol Blood Marrow Transplant; 2016 Feb; 22(2):240-247. PubMed ID: 26256942
[TBL] [Abstract][Full Text] [Related]
80. Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy.
Anandi P; Tian X; Ito S; Muranski P; Chokshi PD; Watters N; Chawla U; Hensel N; Stroncek DF; Battiwalla M; Barrett AJ
Cytotherapy; 2017 Jun; 19(6):735-743. PubMed ID: 28395942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
